HOLON, Israel, December 5, 2016 /PRNewswire/ --
Compugen Ltd. (NASDAQ: CGEN), a leading
predictive drug discovery company, today announced that
Kirk A. Christoffersen has joined
the company in the position of Senior Vice President - Corporate
& Business Development. Mr. Christoffersen, who will be based
at Compugen's South San Francisco facilities, will report to Dr.
Anat Cohen-Dayag, Compugen's
President and Chief Executive Officer, and will have direct
responsibility for the Company's business development strategy and
its execution.
Dr. Cohen-Dayag stated, "We are pleased to welcome Kirk to
Compugen's senior management team at this meaningful time of the
Company's development. Kirk is a seasoned biopharmaceutical
executive who brings to Compugen two decades of impressive
corporate and business development experience and accomplishments
in a variety of biopharmaceutical companies. We are excited to have
the benefit of his experience and capabilities as we advance our
immuno-oncology pipeline and pursue a combination of early and
later stage collaboration opportunities for our product
candidates."
"I am excited to take on this role and look forward to working
with Compugen's senior management and scientific teams as we aim to
realize the potential commercial value of the Company's unique
discovery capabilities, its portfolio of novel immune checkpoint
targets, and most importantly, the product candidates which are now
being pursued by the Company for the development of first-in-class
therapeutics for immuno-oncology," Mr. Christoffersen added.
Kirk Christoffersen has extensive experience in the
biopharmaceutical industry, having held various executive roles in
corporate and business development at GlobeImmune, Inc., OSI
pharmaceuticals, Gilead Sciences and NeXstar Pharmaceuticals. He
holds an undergraduate degree from the University of Michigan, and an M.B.A. from the
Daniels College of Business at the University
of Denver.
About Compugen
Compugen is a leading therapeutic discovery company utilizing
its broadly applicable predictive discovery infrastructure to
identify novel drug targets and develop first-in-class biologics.
The primary focus of the Company's current pipeline is on immune
checkpoint target candidates discovered by the Company, potentially
providing the basis for a next wave of therapeutics for cancer
immunotherapy. Compugen's business model is based on selectively
entering into collaborations for its novel target candidates and
drug product candidates at various stages of research and
development under revenue-sharing agreements. The Company is
headquartered in Israel, with
R&D facilities in Israel and
South San Francisco. At the US facilities, monoclonal antibody
therapeutic candidates are discovered and developed against the
Company's novel target candidates. For additional information,
please visit Compugen's corporate website at
http://www.cgen.com.
Forward-Looking Statement Disclaimer
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements can be identified by the use of
terminology such as "will," "may," "expects," "anticipates,"
"believes," and "intends," and describe opinions about future
events. These forward-looking statements involve known and unknown
risks and uncertainties that may cause the actual results,
performance or achievements of Compugen to be materially different
from any future results, performance or achievements expressed or
implied by such forward-looking statements. Among these risks:
Compugen's business model is substantially dependent on entering
into collaboration agreements with third parties, and Compugen may
not be successful in generating adequate revenues or
commercializing aspects of its business model. Moreover, the
development and commercialization of therapeutic candidates involve
many inherent risks, including failure to progress to clinical
trials or, if they progress to or enter clinical trials, failure to
receive regulatory approval. These and other factors are more fully
discussed in the "Risk Factors" section of Compugen's most recent
Annual Report on Form 20-F as filed with the Securities and
Exchange Commission as well as other documents that may be
subsequently filed by Compugen from time to time with the
Securities and Exchange Commission. In addition, any
forward-looking statements represent Compugen's views only as of
the date of this release and should not be relied upon as
representing its views as of any subsequent date. Compugen does not
assume any obligation to update any forward-looking statements
unless required by law.
Company contact:
Tsipi Haitovsky
Global Media Liaison
Compugen Ltd.
Email: tsipih@cgen.com
Tel: +972-52-598-9892
SOURCE Compugen Ltd.